Latest Research And Development News

Radiopharm Theranostics has secured key ethics approvals to expand its clinical trial portfolio, completed significant preclinical milestones, and raised A$8 million through a strategic placement, while maintaining its cash runway to mid-2026.

InteliCare Holdings Limited reported a positive net cash flow of $30,000 for the December quarter, buoyed by a substantial government R&D rebate. The company ends the quarter with $1.26 million in cash, signaling operational stability amid ongoing funding evaluations.

Unith Ltd has reported its strongest quarterly revenue in two years, driven by its B2C subscription division and strategic partnerships, while advancing its Digital Human technology and expanding into new markets.

Knosys Limited reports a record Annual Recurring Revenue of $9.7 million, driven by major enterprise contract renewals, while gearing up for the March 2025 launch of its Libero Library App.

Bellavista Resources has secured nearly A$5 million in capital to fund due diligence on advanced precious and base metal projects, while maintaining a strong cash position and progressing exploration at its Brumby Deposit.

Latrobe Magnesium marks a year without lost time injuries and completes key construction phases, while navigating legal disputes and operational cost pressures.

Tivan Limited has advanced its Speewah Fluorite Project with a $7.4 million government grant and Major Project Status, alongside a joint venture MoU with Sumitomo Corporation and promising drilling results at Sandover.

Visionflex Group Limited reported a net cash outflow from operations for the December 2024 quarter but secured significant financing, extending its funding runway to nearly 15 quarters.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

Omega Oil and Gas Limited has successfully raised A$7 million in a strongly supported institutional placement, positioning the company to advance its Canyon-1H fracture stimulation and appraisal program.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.